CA2438427C - Methode d'essai de l'effet d'un inhibiteur de l'angiogenese par le biais de l'inhibition de l'expression d'une integrine - Google Patents

Methode d'essai de l'effet d'un inhibiteur de l'angiogenese par le biais de l'inhibition de l'expression d'une integrine Download PDF

Info

Publication number
CA2438427C
CA2438427C CA2438427A CA2438427A CA2438427C CA 2438427 C CA2438427 C CA 2438427C CA 2438427 A CA2438427 A CA 2438427A CA 2438427 A CA2438427 A CA 2438427A CA 2438427 C CA2438427 C CA 2438427C
Authority
CA
Canada
Prior art keywords
substituted
alkyl
atom
integrin
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2438427A
Other languages
English (en)
Other versions
CA2438427A1 (fr
Inventor
Naoto Ono
Taro Senba
Naoko Hata
Yasuhiro Funahashi
Toshiaki Wakabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CA2438427A1 publication Critical patent/CA2438427A1/fr
Application granted granted Critical
Publication of CA2438427C publication Critical patent/CA2438427C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé servant à analyser l'effet d'un médicament sur l'expression d'une intégrine, ledit procédé comprenant la mesure du taux d'expression de l'intégrine dans les plaquettes d'un patient auquel le médicament a été administré, et l'évaluation de l'effet du médicament sur l'expression de l'intégrine dans des cellules autres que les plaquettes, en se basant sur le taux d'expression ainsi mesuré.
CA2438427A 2001-02-21 2002-02-21 Methode d'essai de l'effet d'un inhibiteur de l'angiogenese par le biais de l'inhibition de l'expression d'une integrine Expired - Fee Related CA2438427C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-44646 2001-02-21
JP2001044646 2001-02-21
PCT/JP2002/001562 WO2002066073A1 (fr) 2001-02-21 2002-02-21 Procede servant a analyser l'effet d'un inhibiteur d'angiogenese medie par l'inhibition de l'expression de l'integrine

Publications (2)

Publication Number Publication Date
CA2438427A1 CA2438427A1 (fr) 2002-08-29
CA2438427C true CA2438427C (fr) 2011-04-12

Family

ID=18906601

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2438427A Expired - Fee Related CA2438427C (fr) 2001-02-21 2002-02-21 Methode d'essai de l'effet d'un inhibiteur de l'angiogenese par le biais de l'inhibition de l'expression d'une integrine

Country Status (12)

Country Link
US (1) US7122318B2 (fr)
EP (2) EP1362601B8 (fr)
JP (1) JP4255285B2 (fr)
KR (1) KR20030080013A (fr)
CN (2) CN101025419A (fr)
AT (2) ATE350660T1 (fr)
AU (1) AU2002233677B2 (fr)
CA (1) CA2438427C (fr)
DE (2) DE60229676D1 (fr)
ES (2) ES2280502T3 (fr)
HK (2) HK1059038A1 (fr)
WO (1) WO2002066073A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002233677B2 (en) 2001-02-21 2005-01-06 Eisai R&D Management Co., Ltd. Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression
EP1430894A4 (fr) * 2001-09-05 2007-12-12 Eisai R&D Man Co Ltd Inhibiteur d'activation lymphocytaire et remede pour maladie auto-immune
WO2005090297A1 (fr) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Derives sulfonamides
WO2006090927A1 (fr) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Action orexigenique d'un compose de sulfonamide
PL1893612T3 (pl) 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
WO2007086605A1 (fr) * 2006-01-27 2007-08-02 Eisai R & D Management Co., Ltd. Procédé de prédiction de l'effet d'un composé de sulfonamide
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
EP3873884A1 (fr) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de l'intégrine alpha4bêta7
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
WO2020092401A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOSÉS POUR INHIBITION DE L'INTÉGRINE ALPHA 4β7
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2128648C1 (ru) * 1993-09-10 1999-04-10 Эйсай Ко. Лтд. Производные сульфонамида, способы их получения, фармацевтическая композиция и способ лечения
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
EP0889876B1 (fr) 1996-03-29 2001-07-25 G.D. SEARLE & CO. Derives meta-substitues du sulphonamide de phenylene
SK163598A3 (en) * 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
WO1998044797A1 (fr) * 1997-04-07 1998-10-15 Merck & Co., Inc. Procede de traitement du cancer
US6096707A (en) 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
JP2000247949A (ja) 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
JP4039856B2 (ja) 2000-02-03 2008-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 インテグリン発現阻害剤
AU2002233677B2 (en) 2001-02-21 2005-01-06 Eisai R&D Management Co., Ltd. Method of examining effect of angiogenesis inhibitor mediated by the inhibition of integrin expression

Also Published As

Publication number Publication date
EP1742052A1 (fr) 2007-01-10
JPWO2002066073A1 (ja) 2004-06-17
DE60229676D1 (de) 2008-12-11
ES2317368T3 (es) 2009-04-16
EP1362601A4 (fr) 2005-07-06
DE60217300D1 (de) 2007-02-15
CA2438427A1 (fr) 2002-08-29
ATE412895T1 (de) 2008-11-15
ES2280502T3 (es) 2007-09-16
HK1099363A1 (en) 2007-08-10
ATE350660T1 (de) 2007-01-15
EP1362601B8 (fr) 2007-02-28
US7122318B2 (en) 2006-10-17
HK1059038A1 (en) 2004-06-18
CN101025419A (zh) 2007-08-29
CN1620313A (zh) 2005-05-25
EP1362601A1 (fr) 2003-11-19
WO2002066073A1 (fr) 2002-08-29
EP1362601B1 (fr) 2007-01-03
US20040132783A1 (en) 2004-07-08
KR20030080013A (ko) 2003-10-10
EP1742052B1 (fr) 2008-10-29
JP4255285B2 (ja) 2009-04-15
AU2002233677B2 (en) 2005-01-06
DE60217300T2 (de) 2007-10-04
CN100384482C (zh) 2008-04-30

Similar Documents

Publication Publication Date Title
US7611711B2 (en) VEGFR-3 inhibitor materials and methods
CA2438427C (fr) Methode d'essai de l'effet d'un inhibiteur de l'angiogenese par le biais de l'inhibition de l'expression d'une integrine
JP2003507008A (ja) 後根神経節におけるヒトナトリウムチャンネルの調節
JP7260596B2 (ja) 細胞透過性タンパク質－抗体コンジュゲートおよび使用方法
KR20020053066A (ko) Ａｐｒｉｌ 수용체(ｂｃｍａ) 및 그 용도
CA3070828A1 (fr) Traitement d'etats pathologiques par ciblage direct et indirect de l'interaction sirpa - cd47
KR101886890B1 (ko) 항인간 ｃｃｒ７ 항체, 하이브리도마, 핵산, 벡터, 세포, 의약 조성물 및 항체 고정화 담체
JP3497133B2 (ja) Ａ−３３関連抗原およびそれらの薬理学的使用
KR20210114963A (ko) 암을 치료하기 위한 방법 및 조성물
Singh et al. Functional roles of osteoactivin in normal and disease processes
JPWO2005097204A1 (ja) 癌の予防・治療剤
WO2007026969A1 (fr) Protéine et gène cibles de médicament et méthode de sélection
Winters et al. Three-dimensional culture regulates Raf-1 expression to modulate fibronectin matrix assembly
US20070264263A1 (en) Compositions for Inhibiting Sema7A and VLA-1 Interaction and the Methods of Using the Same
JP2006525784A (ja) 膜貫通型タンパク質ａｍｉｇｏおよびその用途
WO2007123274A1 (fr) Nouveau marqueur CONTRE la SENSIBILITÉ À un COMPOSÉ de sulfonamide
EP2623119B1 (fr) Médicament utilisé dans un procédé de traitement de gliomes, un procédé d'examen de gliomes, un procédé d'administration d'une substance souhaitée à un gliome
EP2843048B1 (fr) NOUVEAU LIGAND DE L'INTÉGRINE alpha9beta1 ET SES UTILISATIONS
Yousafzai et al. Kindlin-2 Regulates the Oncogenic Activities of Integrins and TGF-β In Triple Negative Breast Cancer Progression and Metastasis
EP3250220B1 (fr) Agonistes de la voie s1pr nogo-a pour le traitement du glioblastome
JPWO2005061704A1 (ja) 癌の予防・治療剤
KR20050053628A (ko) 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
KR20140098302A (ko) 디스코이딘 도메인 리셉터 2의 ｊｍ2 도메인의 발현 촉진제를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150223